Abstract
Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease associated with autonomic neuropathy. There is no specific treatment recommendation for autonomic neuropathy (AN) in rheumatic diseases. In addition, there is no study demonstrating therapeutic efficacy of TNF-inhibitor (TNFi) etanercept on autonomic neuropathy in RA. This is the first reported observation of improvement in AN with blockade of TNFi-etanercept in RA. We report a case of a 46-year-old female with severe disease activity treated with subcutaneous etanercept 50mg once a week along with methotrexate 15 mg/week. A significant improvement in cardiovascular autonomic neuropathy and sudomotor function was noted after 6 weeks of treatment.
Highlights
Introductıon Autonomic neuropathy, a well-recognized extra-articular manifestation of rheumatoid arthritis (RA), is first reported by Bennett and Scott in 1965.1 It has been shown to be one of the most important predictors of cardiovascular risk.[2]
Therapeutic effect of diseasemodifying anti-rheumatic drugs (DMARDs) and biologic DMARDs on autonomic neuropathy has been demonstrated in RA and ankylosing spondylitis (AS) patients.[3,4,5]
The present case study describes the improvement of autonomic neuropathy with etanercept in RA
Summary
Ashit Syngle1*, Inderjeet Verma[2], Pawan Krishan[2], Simran Chahal[2], Vijaita Syngle[3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
